– USA, CO – ClinOne, the leader in virtual clinical trial management announced the additions of Jennifer Peters, Albert Prast and Steven Lindseth to its Board of Directors in conjunction with the recent completion of Series A financing.
“The current pandemic is expediting the virtualization of clinical trial management,” said founder and CEO, Rob Bohacs. “Our business has accelerated dramatically due to our proven ability to remotely enable so many aspects of trial management for trial sponsors, sites, and most importantly the patients. With hundreds of trials being managed using our technology in over 55 countries and 30+ languages, ClinOne has the proven experience to meet the societal imperative to virtualize and continue these critical drug trials.”
About Jennifer Peters
Jennifer Peters is a current board member and was the Founder and Chief Experience Officer at Greenphire – a leading clinical trial technology company which revolutionized clinical trial patient reimbursement and site payment processes. Jennifer has also held several other executive-level Life Sciences positions formerly serving as the Senior Vice President of Scientific Services at Bracket and Vice-President, Life Sciences at TransPerfect.
“ClinOne’s approach to the virtual management of clinical trials was always the future of the industry, but COVID has expedited the timeline to ‘now.’ Every trial sponsor, CRO and site will need to evaluate how trial management technology can ensure trial continuity during the pandemic. ClinOne is well-positioned to meet the increasing industry demand to strengthen communication between sponsors, sites, and patients,” said Jennifer Peters. “After having spent more than 15 years in the industry, I am more convinced than ever that companies will need to quickly innovate in order to continue the research that is so important. COVID-19 has exposed critical vulnerabilities in the traditional trial management process – giving ClinOne a tremendous opportunity to provide sponsors with proven solutions that will enable virtualization.”
About Albert Prast
Albert Prast has led executive technology organizations in the healthcare technology industry for 25 years. He is an operating partner and advisor to numerous private equity firms. Currently, Albert serves as the Chief Information and Chief Technology Officer for AeroCare Holdings, a national leader in the durable medical equipment industry. Albert is also an active investor and advisor to healthcare technology companies and serves on the boards of RxRevu, DataLink Software, NucleusHealth, Revel Health, and VectorCare.
About Steven Lindseth
Steven Lindseth is a General Partner at the CU Healthcare Innovation Fund, which led the Series A financing. Steve has been a healthcare IT/digital health entrepreneur, operator and investor for over 30 years. He co-founded and invested in world-class healthcare devices, technology-enabled services, digital media and enterprise software companies. He also serves on the boards of RxRevu and Conversa Health.
About ClinOne
The ClinOne solution and its suite of products are proven to accelerate clinical trial enrollment and remote patient care, compliance and retention. The company’s sole mission is to strengthen the connectively and management of participating researchers, patients, and caregivers on-site and remotely. ClinOne’s systems are HIPAA, FDA CRF 21 Part 11, and GDPR compliant and validated and have been used across 55 countries by more than 30 sponsors and 90,000 investigators since 2016.
For more information: https://www.clinone.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.